Daiwa Securities Group Inc. Summit Therapeutics Inc. Transaction History
Daiwa Securities Group Inc.
- $23.7 Billion
- Q1 2025
A detailed history of Daiwa Securities Group Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 14,259 shares of SMMT stock, worth $376,295. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,259
Previous 2,434
485.83%
Holding current value
$376,295
Previous $43,000
539.53%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$645 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$307 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$208 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$173 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$128 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.31B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...